MX2019004845A - Procedimientos para la formacion de complejos de ciclodextrina para formular inhibidores del proteasoma peptidico. - Google Patents

Procedimientos para la formacion de complejos de ciclodextrina para formular inhibidores del proteasoma peptidico.

Info

Publication number
MX2019004845A
MX2019004845A MX2019004845A MX2019004845A MX2019004845A MX 2019004845 A MX2019004845 A MX 2019004845A MX 2019004845 A MX2019004845 A MX 2019004845A MX 2019004845 A MX2019004845 A MX 2019004845A MX 2019004845 A MX2019004845 A MX 2019004845A
Authority
MX
Mexico
Prior art keywords
proteasome inhibitors
methods
cylodextrin
peptide proteasome
complexation
Prior art date
Application number
MX2019004845A
Other languages
English (en)
Inventor
Sean Dalziel
Evan Lewis
Peter Shwonek
Mouhannad Jumaa
Original Assignee
Onyx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48326170&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019004845(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Onyx Therapeutics Inc filed Critical Onyx Therapeutics Inc
Publication of MX2019004845A publication Critical patent/MX2019004845A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood

Abstract

La presente divulgación proporciona procedimientos para formular composiciones que comprenden uno o más inhibidores del proteasoma peptídico y una ciclodextrina, en particular una ciclodextrina sustituida. Dichos procedimientos incrementan considerablemente la solubilidad y la estabilidad de estos inhibidores del proteasoma y facilitan tanto su fabricación como su administración.
MX2019004845A 2012-05-08 2014-11-07 Procedimientos para la formacion de complejos de ciclodextrina para formular inhibidores del proteasoma peptidico. MX2019004845A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261644122P 2012-05-08 2012-05-08
US201361777475P 2013-03-12 2013-03-12

Publications (1)

Publication Number Publication Date
MX2019004845A true MX2019004845A (es) 2021-03-31

Family

ID=48326170

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014013552A MX364393B (es) 2012-05-08 2013-05-08 Procedimientos para la formacion de complejos de ciclodextrina para formular inhibidores del proteasoma peptidico.
MX2019004845A MX2019004845A (es) 2012-05-08 2014-11-07 Procedimientos para la formacion de complejos de ciclodextrina para formular inhibidores del proteasoma peptidico.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2014013552A MX364393B (es) 2012-05-08 2013-05-08 Procedimientos para la formacion de complejos de ciclodextrina para formular inhibidores del proteasoma peptidico.

Country Status (14)

Country Link
US (1) US10159746B2 (es)
EP (1) EP2662094B1 (es)
JP (1) JP6410264B2 (es)
KR (4) KR20220088949A (es)
CN (2) CN104411334A (es)
AU (2) AU2013259573B2 (es)
CA (1) CA2873044C (es)
CL (1) CL2014003055A1 (es)
EA (1) EA033614B1 (es)
HK (2) HK1207827A1 (es)
IL (1) IL235553B (es)
MX (2) MX364393B (es)
SG (2) SG10201609318UA (es)
WO (1) WO2013169897A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015009888A2 (en) 2013-07-19 2015-01-22 Onyx Therapeutics, Inc. Peptide epoxyketone proteasome inhibitors in combination with pim kinase inhibitors for treatment of cancers
CN104945470B (zh) * 2014-03-30 2020-08-11 浙江大学 杂环构建的三肽环氧酮类化合物及制备和应用
LT3478670T (lt) 2016-06-29 2023-05-25 Kezar Life Sciences Kristalinės peptidų epoksiketono imunoproteasomų inhibitoriaus druskos
IL263771B2 (en) 2016-06-29 2023-09-01 Kezar Life Sciences Preparation process of immunoproteasome epoxytone peptide inhibitor and its precursors
WO2018038687A1 (en) 2016-08-22 2018-03-01 Mustafa Nevzat Ilaç Sanayii A.Ş. Pharmaceutical formulations comprising a bortezomib-cyclodextrin complex
KR102525438B1 (ko) 2016-11-29 2023-04-26 오쿨리스 에스에이 안과용 활성 약학 성분 전달을 위한 고형 사이클로덱스트린 복합체의 제조
AU2018263924A1 (en) * 2017-05-03 2019-11-21 Cydex Pharmaceuticals, Inc. Composition containing cyclodextrin and busulfan
CN110882221B (zh) * 2019-11-29 2021-06-29 健进制药有限公司 一种注射用卡非佐米冻干制剂的生产工艺
WO2022159319A2 (en) * 2021-01-19 2022-07-28 Mountain Valley Md Inc A porous aluminum nanoparticulate structure

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE19505263A1 (de) * 1995-02-16 1996-08-22 Consortium Elektrochem Ind Verfahren zur Reinigung von wasserlöslichen Cyclodextrinderivaten
AU4499697A (en) 1996-09-13 1998-04-02 New York University Method for treating parasitic diseases with proteasome inhibitors
US6042820A (en) 1996-12-20 2000-03-28 Connaught Laboratories Limited Biodegradable copolymer containing α-hydroxy acid and α-amino acid units
GB9713149D0 (en) 1997-06-21 1997-08-27 Pfizer Ltd Pharmaceutical formulations
EP0889056B1 (en) 1997-07-01 2006-04-12 Pfizer Products Inc. Process for making a cyclodextrin
US6472375B1 (en) 1998-04-16 2002-10-29 John Wayne Cancer Institute DNA vaccine and methods for its use
US6831099B1 (en) 1999-05-12 2004-12-14 Yale University Enzyme inhibition
DK1326632T3 (da) 2000-10-12 2007-01-15 Viromics Gmbh Protease-inhibitorer til behandling af infektioner af hepatitisvirus
BRPI0418386A (pt) * 2003-12-31 2007-05-22 Cydex Inc formulação inalante contendo éter sulfoalquìlico gama-ciclodextrina e corticosteróide
US7232818B2 (en) 2004-04-15 2007-06-19 Proteolix, Inc. Compounds for enzyme inhibition
CN103554222A (zh) 2004-04-15 2014-02-05 欧尼斯治疗公司 用于抑制蛋白酶体酶的化合物
ATE499109T1 (de) * 2004-12-07 2011-03-15 Proteolix Inc Zusammensetzung zur proteasomhemmung
CA2626122A1 (en) * 2005-11-15 2007-05-24 Baxter International, Inc. Compositions comprising lipoxygenase inhibitors and cyclodextrin
MY173938A (en) * 2007-10-04 2020-02-27 Onyx Therapeutics Inc Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
PE20120059A1 (es) * 2008-10-21 2012-02-27 Onyx Therapeutics Inc Combinaciones farmaceuticas con epoxicetonas peptidicas
US9493582B2 (en) 2012-02-28 2016-11-15 Cydex Pharmaceuticals, Inc. Alkylated cyclodextrin compositions and processes for preparing and using the same

Also Published As

Publication number Publication date
KR102054329B1 (ko) 2019-12-10
KR20150008165A (ko) 2015-01-21
JP2015516430A (ja) 2015-06-11
SG10201609318UA (en) 2016-12-29
US20150111838A1 (en) 2015-04-23
EA201491994A1 (ru) 2015-04-30
IL235553A0 (en) 2015-01-29
CA2873044A1 (en) 2013-11-14
EA033614B1 (ru) 2019-11-11
AU2013259573A1 (en) 2014-11-27
KR20200130748A (ko) 2020-11-19
AU2013259573B2 (en) 2018-02-15
HK1250927A1 (zh) 2019-01-18
EP2662094B1 (en) 2024-04-17
CN107693772A (zh) 2018-02-16
CA2873044C (en) 2021-01-26
CL2014003055A1 (es) 2015-02-13
JP6410264B2 (ja) 2018-10-24
AU2018200444B2 (en) 2019-10-31
EP2662094A1 (en) 2013-11-13
KR20190137963A (ko) 2019-12-11
MX2014013552A (es) 2015-05-08
HK1207827A1 (en) 2016-02-12
SG11201407337QA (en) 2014-12-30
KR20220088949A (ko) 2022-06-28
IL235553B (en) 2018-04-30
WO2013169897A1 (en) 2013-11-14
AU2018200444A1 (en) 2018-02-08
US10159746B2 (en) 2018-12-25
MX364393B (es) 2019-04-24
CN104411334A (zh) 2015-03-11

Similar Documents

Publication Publication Date Title
MX2019004845A (es) Procedimientos para la formacion de complejos de ciclodextrina para formular inhibidores del proteasoma peptidico.
MY196510A (en) Cylodextrin Complexation Methods for Formulating Peptide Proteasome Inhibitors
CY1124690T1 (el) Σκευασματα ενδοφλεβιου διαλυματος ποσακοναζολης σταθεροποιημενα με υποκατεστημενη βητα-κυκλοδεξτρινη
AU2012214029A8 (en) Rorgammat inhibitors
UA105229C2 (uk) Фармацевтичний склад
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
EA201490724A1 (ru) Замещенные соединения тетрагидроизохинолина в качестве ингибиторов фактора xia
EA201390908A1 (ru) Производные бицикло[3.2.1]октиламида и их применение
IN2014CN02806A (es)
MX2013007336A (es) Compuestos de bi-heteroarilo como inhibidores de vps34.
TN2015000324A1 (en) Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
WO2013009527A3 (en) Factor ixa inhibitors
UA109281C2 (uk) Фармацевтична композиція, яка містить похідне аміду або його фармацевтично прийнятну сіль
EP3995489A3 (en) Disulfide compounds for delivery of pharmaceutical agents
EA201291014A1 (ru) Трициклическое индазольное соединение, способ его получения и содержащая его фармацевтическая композиция
TN2014000060A1 (en) Benzothiazolone compound
PH12015501146A1 (en) Hydantoin derivative
MX343540B (es) Compuesto de tiazol y metodo de preparacion y uso del mismo.
MX2019012375A (es) Formulaciones del inhibidor del antigeno-1 asociado a la funcion de linfocitos (lfa-1).
EP4282973A3 (en) Processes for the preparation of pyrimidinylcyclopentane compounds
SMT201300112B (it) Sale citrato di 9E-15-(2-pirrolidin-1-il-etossi)-7,12,25-triossa-19,21,24-triaza-tetracicloÄ18.3.1.1(2,5).1(14,18)Üesacos a-1(24),2,4,9,14,16,18(26),20,22-nonaene
MX2015010434A (es) Derivados de acido bisfenil-butanoico sustituido como inhibidores de la endopeptidasa neutra (nep), con una mayor eficacia in vivo.
MX2015017864A (es) Metodo de preparacion de derivados de acido pirrolidina-2-carboxil ico.
SA114350532B1 (ar) عملية لتخليق 3، 4-داي ميثوكسي باي سيكلو [4، 2، 0] أوكتا-1، 3، 5- ترايين-7-كربو نيتريل، والاستخدام في تخليق إيفابرادين وأملاح إضافة منه باستخدام حمض مقبول صيدلانياً
TN2015000058A1 (en) Salts of benzothiazolone compound as beta-2-adrenoceptor agonist